CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with domestic firm Carcell Biopharma, a developer of medical technology service platforms. The collaboration will focus on technical cooperation in the global development of Lipid Nanoparticle (LNP) delivered mRNA and other nucleic acid drugs, aiming to expedite the clinical and commercial deployment of these drugs.
CATUG possesses technology platforms for plasmid manufacturing, mRNA synthesis, LNP delivery, and nucleic acid analysis, offering comprehensive CRDMO services to clients worldwide. Carcell Biopharma, on the other hand, is dedicated to advancing the development of next-generation cell and gene therapies and boasts a proprietary liposome library consisting of 1,500 cationic lipids.- Flcube.com
